THOMAS MONATH to Encephalitis Virus, Japanese
This is a "connection" page, showing publications THOMAS MONATH has written about Encephalitis Virus, Japanese.
Connection Strength
2.731
-
Japanese Encephalitis: Risk of Emergence in the United States and the Resulting Impact. Viruses. 2023 12 28; 16(1).
Score: 0.892
-
Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences. Vaccine. 2007 Nov 19; 25(47):8077-84.
Score: 0.289
-
Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). Am J Trop Med Hyg. 2006 Oct; 75(4):659-63.
Score: 0.270
-
Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol. 2002 Feb; 76(4):1932-43.
Score: 0.195
-
Japanese encephalitis vaccines: current vaccines and future prospects. Curr Top Microbiol Immunol. 2002; 267:105-38.
Score: 0.194
-
Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol. 2000 Feb; 74(4):1742-51.
Score: 0.170
-
Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 1999 May 10; 257(2):363-72.
Score: 0.162
-
Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine. 1999 Apr 09; 17(15-16):1869-82.
Score: 0.161
-
Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J Infect Dis. 1990 May; 161(5):878-82.
Score: 0.086
-
A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus. Virology. 2007 Jun 05; 362(2):468-74.
Score: 0.069
-
Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine. 2004 Sep 09; 22(27-28):3722-6.
Score: 0.059
-
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003 Oct 15; 188(8):1213-30.
Score: 0.055
-
Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol. 2001 Jan; 75(2):934-42.
Score: 0.045
-
Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am J Trop Med Hyg. 2000 Apr; 62(4):480-4.
Score: 0.043
-
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010 Jan 08; 28(3):632-49.
Score: 0.021
-
Japanese encephalitis--a plague of the Orient. N Engl J Med. 1988 Sep 08; 319(10):641-3.
Score: 0.019